GreenLight Announces Completion of Merger with Fall Line Endurance Fund
About 67% of Greenlight Biosciences' investor base is looking to short. The analysis of current outlook of investing in Greenlight Biosciences Holdings suggests that many traders are alarmed regarding Greenlight Biosciences' prospects. The current market sentiment, together with Greenlight Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Greenlight Biosciences stock news signals to limit their universe of possible portfolio assets.
Greenlight |
LEXINGTON, Mass., July 24, 2023 GreenLight Biosciences Holdings, PBC today announced the closing of its previously announced merger with SW MergerCo,
Read at benzinga.com
![]() |
Greenlight Biosciences Fundamental Analysis
We analyze Greenlight Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Greenlight Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Greenlight Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Greenlight Biosciences is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Greenlight Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Greenlight Biosciences stock to make a market-neutral strategy. Peer analysis of Greenlight Biosciences could also be used in its relative valuation, which is a method of valuing Greenlight Biosciences by comparing valuation metrics with similar companies.
Peers
Greenlight Biosciences Related Equities
QNRX | Quoin Pharmaceuticals | 14.58 | ||||
ZVSA | ZyVersa Therapeutics | 4.46 | ||||
LGVN | Longeveron LLC | 3.38 | ||||
LEXX | Lexaria Bioscience | 1.31 | ||||
VRAX | Virax Biolabs | 1.18 | ||||
BDRX | Biodexa Pharmaceticals | 0.86 | ||||
RNXT | RenovoRx | 0.99 | ||||
REVB | Revelation Biosciences | 1.67 | ||||
NTRB | Nutriband | 2.57 | ||||
SNTI | Senti Biosciences | 4.69 | ||||
FHTX | Foghorn Therapeutics | 7.58 | ||||
CVKD | Cadrenal Therapeutics, | 9.29 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Greenlight Stock
If you are still planning to invest in Greenlight Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Greenlight Biosciences' history and understand the potential risks before investing.
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |